Fulviglen 250Mg/5Ml Inj belongs to the class of estrogen blockers used to treat breast cancer in postmenopausal women. Breast cancer is a type of cancer that develops when the breast cells begin to grow abnormally.
Fulviglen 250Mg/5Ml Inj contains Fulvestrant, which works by inhibiting some of the actions of estrogen (female sex hormone which may help cancer cells grow in women with breast cancer) and reducing the amount that is in the body. Thus, it helps in reducing breast cancer tumour growth.
Fulviglen 250Mg/5Ml Inj will be administered by a healthcare professional; do not self-administer. In some cases, Fulviglen 250Mg/5Ml Inj may cause certain common side effects such as injection site reactions like pain and/or inflammation, weakness, nausea, tiredness, headache or joint and musculoskeletal pain. Most of these side effects of Fulviglen 250Mg/5Ml Inj do not require medical attention and gradually resolve over time. However, if these side effects persist or worsen, please consult your doctor.
If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Fulviglen 250Mg/5Ml Inj is not recommended for pregnant women as it may harm an unborn baby. Fulviglen 250Mg/5Ml Inj is contraindicated for use during lactation. Avoid alcohol consumption while receiving Fulviglen 250Mg/5Ml Inj. Avoid driving or operating machinery if you feel tired or weak after receiving Fulviglen 250Mg/5Ml Inj.